Annals of Neurology published the study.
Here are five takeaways:
1. Zee-A Han, MD, PhD, and his team tested the efficacy of subcutaneous botulinum toxin type A injections in 40 patients with spinal cord injury-associated neuropathic pain.
2. The researchers analyzed pain and quality of life at four weeks and eight weeks post-injection.
3. Of the patients receiving BTX-A, 45 percent reported pain relief of at least 20 percent eight weeks post-injection. Only 10 percent of patients who did not receive BTA-injections reported pain relief of 20 percent eight weeks post-injection.
4. Pain relief was associated with motor and sensor function below the injury level.
5. The researchers concluded BTA-X may decrease neuropathic pain in spinal cord injury patients.
More articles on spine:
Lumbar spinal fusion: 5 key notes on adjacent segment disease & disorder
Minimally invasive SI joint fusion surgery a solution to low back pain — 5 things to know
Oxford University Press journals adds Pain Medicine — 4 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.